John Gillard, CEO of Trinity Biotech, emphasized that their patented technology is set to disrupt the CGM market, which is expected to surpass $20 billion by 2029. He highlighted the ergonomic ...
Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management.
We are developing a CGM system that is not only highly accurate but also disruptively affordable and user-friendly,” said John Gillard, CEO of Trinity Biotech. “The two largest CGM ...
(RTTNews) - Trinity Biotech plc (TRIB), a biotechnology company ... for its next-generation continuous glucose monitoring or CGM system. The findings show approximately 35 percent improvement ...
Research analysts at StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Free Report) in a report released on Wednesday. The firm set a “hold” rating on the stock. Trinity ...
Shares of Trinity Biotech (NASDAQ:TRIB ... pivotal clinical trial for its next-gen continuous glucose monitoring (CGM) system. Based on data from 30 diabetic patients, Trinity (NASDAQ:TRIB ...
Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc ...
Trinity announced results from its pre-pivotal clinical trial for continuous glucose monitoring system. The trial results indicated a 25% to 30% improvement in accuracy over earlier CGM sensors.
Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market.
Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech ...